Topical delgocitinib, a pan-Janus kinase inhibitor, showed promise in treating moderate to severe chronic hand eczema in two phase 3 trials involving nearly 1000 patients. Patients using delgocitinib experienced reduced severity and symptoms of the condition compared to those using a placebo cream. The treatment was well tolerated, with most adverse events being mild to moderate and not related to the medication. Delgocitinib also significantly reduced itch and pain associated with eczema. The study suggests that delgocitinib cream is an effective and safe treatment option for adults with chronic hand eczema. However, the findings may not be generalizable to more diverse populations, and the long-term effects of the medication require further study.
Source link
Delgocitinib Effective for Hand Eczema in Phase 3 Studies
